Your browser doesn't support javascript.
loading
SWEDEGENE-a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions.
Hallberg, Pär; Yue, Qun-Ying; Eliasson, Erik; Melhus, Håkan; Ås, Joel; Wadelius, Mia.
Afiliación
  • Hallberg P; Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. par.hallberg@medsci.uu.se.
  • Yue QY; WHO Uppsala Monitoring Center, Uppsala, Sweden.
  • Eliasson E; Karolinska Institutet, Department of Laboratory Medicine, Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.
  • Melhus H; Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Ås J; Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Wadelius M; Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Pharmacogenomics J ; 20(4): 579-585, 2020 08.
Article en En | MEDLINE | ID: mdl-31949290
ABSTRACT
SWEDEGENE is a Swedish nation-wide sample collection established to facilitate studies of clinical and genetic risk factors for adverse drug reactions (ADRs). Most cases are recruited among patients reported to the ADR registry at the Swedish Medical Products Agency by health-care professionals. Clinical data are collected both from medical and laboratory records and through interviews using standardized questionnaires. Genome-wide scans and whole-genome sequencing are done, and association studies are conducted using mainly controls from the Swedish TwinGene biobank with data on diagnoses and prescribed drugs. SWEDEGENE was established in 2008 and currently contains DNA and information from about 2550 adults who have experienced specific ADRs, and from 580 drug exposed controls. Results from genome-wide association studies have now been published, and data from whole-genome sequencing are being analyzed. SWEDEGENE has the potential to offer a new means of developing individualized and safe drug therapy through patient pre-treatment screening.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gemelos / ADN / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Estudio de Asociación del Genoma Completo / Pruebas de Farmacogenómica Tipo de estudio: Diagnostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Pharmacogenomics J Asunto de la revista: BIOLOGIA MOLECULAR / FARMACOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gemelos / ADN / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Estudio de Asociación del Genoma Completo / Pruebas de Farmacogenómica Tipo de estudio: Diagnostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Pharmacogenomics J Asunto de la revista: BIOLOGIA MOLECULAR / FARMACOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Suecia
...